Karo Bio's next act

Pfizer deal unlocks value in Karo Bio's preclinical programs

Karo Bio AB thinks its deal with Pfizer Inc. will change the common perception that the company has nothing of value but eprotirome.

Eprotirome, a thyroid hormone receptor agonist, is in the Phase III AKKA trial in 630 patients with heterozygous familial hypercholesterolemia (HeFH). Interim three-month data from the first 150 patients are expected in 2Q12.

Last October, Karo Bio decided to spin out its preclinical operations into a subsidiary to separate them from eprotirome and to sharpen the company's focus, President and CEO Per Bengtsson told BioCentury. "It's

Read the full 877 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE